Granules India revenue increases by 10 percent to Rs 386 Crore
HYDERABAD: Granules India Ltd., a growing pharmaceutical manufacturing company, announced financial results for its first quarter ended 30th June, 2017.
Quarterly Financial Highlights of Q1-FY18:
| Consolidated | Standalone | |
| Revenue: | Rs. 386 Cr. | Rs. 396 Cr. |
| EBITDA: | Rs. 77 Cr. | Rs. 79 Cr. |
| Net Profit: | Rs. 37 Cr. | Rs. 36 Cr. |
The Company's Board of Directors has approved interim dividend of 25 paise per share of face value of Re. 1 each.
Granules Omnichem Private Limited (JV) has not contributed to the profit growth for this quarter as most of the orders shall be delivered in the subsequent quarters due to cyclical nature of the business.
"I am happy to state that the current year has started with a positive note. While our journey towards transformation by developing newer avenues continues, we remain focused on strengthening our base business. Our vertical integration across core business products is one of our key strengths and it will continue to differentiate us. We shall continue to build on our strengths by commercializing additional API and PFI capacities during the year and this will enable us to maintain our steady financial performance," said Mr. Krishna Prasad Chigurupati, Chairman and Managing Director.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd